Download Powerful Vaccine Discovery

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Immunomics wikipedia , lookup

Thiomersal controversy wikipedia , lookup

Vaccination policy wikipedia , lookup

Globalization and disease wikipedia , lookup

DNA vaccination wikipedia , lookup

Orthohantavirus wikipedia , lookup

Jonas Salk wikipedia , lookup

Cysticercosis wikipedia , lookup

Herd immunity wikipedia , lookup

Whooping cough wikipedia , lookup

Childhood immunizations in the United States wikipedia , lookup

Non-specific effect of vaccines wikipedia , lookup

Vaccine wikipedia , lookup

HIV vaccine wikipedia , lookup

Immunocontraception wikipedia , lookup

Vaccination wikipedia , lookup

Transcript
Vaccine
Discovery
Licensing Technology
Powerful Vaccine Discovery
Therapeutic vaccines have the potential to
reach large populations and prevent endemic
disease. Using novel technologies such as
flagellin-based fusion proteins, scientists at
Wake Forest Baptist Medical Center and Wake
Forest University are developing highly potent,
cost-effective vaccines that provide protective
immunity against a range of illnesses.
These new vaccine technologies are available for licensing and further development
by industry partners and investment organizations:
Pneumonic Plague Vaccine
Vaccine Against Pneumococcus
This vaccine uses a fusion protein that comprises flagellin
and the F1- and V-antigens of Yersinia pestis, resulting
in powerful immunity against pneumonic plague. It has
significant potential to be the first approved vaccine for
pneumonic plague.
(Ref # WFU 05-13)
This vaccine uses a fusion protein of flagellin and various
pspA antigens to provide protection against multiple
disease-causing pneumococcal serotypes.
(Ref # WFU 09-50)
Pseudomonas Aeruginosa Vaccine
This vaccine produces a robust immune response to
Pseudomonas aeruginosa, a major cause of morbidity and
mortality in cystic fibrosis and ventilated patients, using a
fusion protein of flagellin and the OprI and OprF antigens.
(Ref # WFU 09-14)
Vaccine against Drugs of Abuse
Vaccine therapies comprised of a drug-flagellin conjugate
are in development to promote long-lasting, high level of
immunity to drugs of abuse.
(Ref # WFU 09-56)
Breast Cancer Vaccine
This vaccine, which selectively targets breast cancer
cells, consists of a fusion protein of flagellin and the
Fra-1 antigen.
(Ref # 05-13)
Vaccine for Bordetella Bronchisepticamediated Respiratory Infections
This acellular Bordetella bronchiseptica vaccine is
comprised of the immunogenic BcfA (Bordetella
colonization factor A) protein, which establishes protective
immunity in vivo against Bordetella infections without the
risk of subsequent infection by the vaccine strain
and disease.
(Ref # WFU 08-11)
About Wake Forest Innovations
Wake Forest Innovations commercializes technology, products
and services arising from the discoveries and scientific assets
of Wake Forest Baptist Medical Center and Wake Forest
University. The enterprise facilitates innovation and partners
our proprietary technology; enables other organizations
and companies to access our scientific assets; and develops
the Innovation Quarter as a locale for creative innovation in
biomedicine and information technology.
Wake Forest Innovations
Wake Forest Biotech Place
575 N. Patterson Ave., Suite 550
Winston-Salem, NC 27101
WakeForestInnovations.com
[email protected]
+1.336.716.8508